Loading...
Mersana Therapeutics reported their Q4 and Full Year 2022 financial results, highlighting advancements in their lead product candidate UpRi, diversification of their clinical pipeline, new collaborations, and a strengthened financial position.
Advanced UpRi in multiple clinical trials.
Diversified clinical pipeline.
Entered significant new collaborations.
Strengthened financial position.
Analyze how earnings announcements historically affect stock price performance